European Commission recognises Lifecare innovations in implantable glucose monitoring

12 Mar 2026 07:00 CET

Bergen, Norway 12 March 2026 - Lifecare ASA, a MedTech company developing
next-generation implantable Continuous Glucose Monitoring (CGM) technology,
announces that two innovations developed within the EU-funded FORGETDIABETES
project have been published on the European Commission's Innovation Radar
platform.

Lifecare has been recognised as a Key Innovator in connection with the
following innovations:

* Osmotic pressure-based implantable intra-peritoneal sensor for continuous
glucose monitoring
* Method to stabilise Concanavalin A for temperature stability of sensor
operation

The Innovation Radar is an initiative of the European Commission that
identifies high-potential innovations and innovators emerging from EU-funded
research and innovation programmes.

Recognition of core platform technology
The osmotic pressure-based implantable sensor represents the fundamental
sensing principle underlying Lifecare's proprietary CGM platform. Unlike
traditional enzyme-based CGM systems, the technology leverages osmotic
pressure variations to measure glucose levels, enabling a fully implantable
and long-duration glucose monitoring solution.

The second recognised innovation relates to stabilisation methods for key
biochemical components used within the sensing mechanism. Improved stability
of these components supports reliable long-term sensor operation and
contributes to the robustness of the sensing platform.

Both innovations have been identified by the European Commission as having
potential relevance for future standardisation activities.

Supporting technology development
Lifecare continues the development of its implantable CGM technology, focusing
on validating the underlying sensing platform and advancing the system toward
future clinical evaluation.

Publication on the Innovation Radar platform highlights the scientific
foundation of Lifecare's technology and reflects the contribution of
EU-supported research to the advancement of new approaches in glucose
monitoring.

"Being recognised as a Key Innovator by the European Commission highlights the
strength of the scientific foundation behind our technology", says Joacim
Holter, CEO of Lifecare. "Our focus remains on translating innovation into
practical solutions that can contribute to improved glucose monitoring and
diabetes management."

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

668072_European Commission recognises Lifecare innovations in implantable glucose monitoring.pdf